Skip to main content
    C

    Cardiff Oncology Inc (CRDF)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.85
    -0.00 (-0.15%)

    Market Cap: $65.95M

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Cardiff Oncology Inc (CRDF) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cardiff Oncology (CRDF) has a market cap of $65.95M and an enterprise value of $53.89M. It kept -6735.24% of revenue as net income over the last 12 months. Its share count is up 13.90% from a year earlier.

    Total Valuation

    Enterprise value is 18.29% below the market cap, as cash exceeds debt.

    Market Cap$65.95M
    Enterprise Value$53.89M
    Latest price (Nov 17, 2026)$0.85

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 11.38% in the quarter ended Sep 30, 2026 and grew 27.49% a year over 2 years.

    Shares Outstanding76.18M
    Shares Change (YoY)+13.90%
    Shares Change (QoQ)+11.38%
    Share Count Growth (2Y CAGR)+27.49%

    Valuation Ratios

    Sales and book value multiples are 115.3x and 2.3x. Its year-end P/S ranged from 11.8x to 866.8x from 2016 to 2025.

    P/S Ratio115.3x
    Forward P/S180.9x
    P/B Ratio2.3x

    Valuation history and multiples

    Price Statistics

    The stock is down 60.26% over 52 weeks and trades 17.48% below its 50-day average.

    Beta (1Y)1.64
    52-Week Change-60.26%
    1-Month Change-4.44%
    3-Month Change-5.74%
    6-Month Change-51.91%
    5-Year Change-84.84%
    10-Year Change-99.64%
    Total Return (1Y)-60.26%
    Total Return (3Y CAGR)-10.98%
    Total Return (5Y CAGR)-32.89%
    Max Drawdown (1Y)-77.38%
    Max Drawdown (3Y)-87.71%
    Sharpe Ratio (1Y)-0.93
    Correlation with SPY (1Y)0.24
    50-Day Average$1.03
    200-Day Average$1.34
    52-Week Range$0.71 to $3.31
    RSI (14 Days)46.5
    Average Volume (20 Days)1.71M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.21x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.21x
    Quick Ratio4.21x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -134.00% over the last 12 months, against a 5-year average of -54.35%.

    Return on Equity (ROE)-134.00%
    Return on Assets (ROA)-103.39%
    ROE (5Y Average)-54.35%
    ROA (5Y Average)-44.77%
    ROIC (5Y Average)-85.21%
    Asset Turnover0.01x
    Receivables Turnover4.01x

    Scores

    CRDF has an Altman Z-Score of -15.74, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-15.74
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $559.00K over the last 12 months is up 11.80% from the 12 months before.

    Revenue$559.00K
    Revenue Growth (YoY)+11.80%
    Gross Profit$559.00K
    Operating Income-$39.51M
    Pretax Income-$37.65M
    Net Income-$37.65M
    Reported EPS (TTM)-$0.55

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 77.18% of the $36.41M in total assets.

    Cash and Equivalents$12.06M
    Total Debt$0
    Net Cash$12.06M
    Net Cash Per Share$0.16
    Working Capital$26.71M
    Shareholder Equity$28.10M
    Book Value Per Share$0.37
    Total Assets$36.41M
    Total Liabilities$8.32M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $48.00K of capital spending, operating cash flow left -$39.94M of free cash flow.

    Operating Cash Flow-$39.89M
    Capital Expenditures$48.00K
    Free Cash Flow-$39.94M
    FCF Per Share-$0.51
    Depreciation and Amortization$1.14M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -7068.16%.

    Gross Margin100.00%
    Operating Margin-7068.16%
    Pretax Margin-6735.24%
    Net Margin-6735.24%
    FCF Margin-7145.26%

    Growth

    Revenue grew 15.39% a year over 3 years.

    Revenue Growth (3Y CAGR)+15.39%
    Revenue Growth (5Y CAGR)+10.13%
    Book Value Per Share Growth (2Y CAGR)-34.04%
    Tangible Book Per Share Growth (2Y CAGR)-34.04%

    Revenue and profit by year

    Dividends and Yields

    CRDF does not pay a dividend. Its free cash flow yield is -61.95%.

    FCF Yield-61.95%
    Buyback Yield1.25%
    Shareholder Yield1.25%

    Stock Splits

    The last split was a 1-for-6 reverse split on Feb 20, 2019.

    Last Split DateFeb 20, 2019
    Split TypeReverse split
    Split Ratio1:6

    Peer Position

    Against 5 similar companies, CRDF has the highest P/S.

    P/S Ratio115.3x vs 12.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+11.80% vs -21.38% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -19.42% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-19.42%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CRDF

    What is CRDF's market cap?

    Cardiff Oncology has a market cap of $65.95M. Its enterprise value, which adds debt and subtracts cash, is $53.89M.

    How many shares of CRDF are outstanding?

    Cardiff Oncology has 76.18M shares outstanding. The count is up 13.90% from a year earlier.

    Does CRDF pay a dividend?

    No. Cardiff Oncology does not pay a dividend.

    How much debt does CRDF have?

    Cardiff Oncology has $0 of total debt and $12.06M of cash and equivalents, a net cash position of $12.06M.